Eli Lilly has elected Prof Carolyn Bertozzi to its board of directors, where she will serve as a member of the science and technology, public policy and compliance committees.
Prof Bertozzi is currently the Anne T and Robert M Bass professor of chemistry and professor of chemistry and systems biology and radiology at Standford University, and serves as an investigator at the Howard Hughes Medical Institute.
She first joined Stanford in 2015 with the launch of its ChEM-H Institute, having previously been a member of the UC Berkley College of Chemistry.
Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection to develop diagnostic and therapeutic approaches.
Prof Bertozzi is a member of the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences.
Dr John Lechleiter, chairman of Eli Lilly’s board of directors, said: “We are very pleased to welcome Carolyn Bertozzi to the Lilly board.
“Professor Bertozzi, with her broad scientific expertise and solid record of accomplishment, along with her understanding of the biopharmaceutical industry, will contribute greatly to our board and our company as we seek to advance Lilly’s pipeline of potential new medicines to benefit patients and our other key stakeholders.”